Volume : 08, Issue : 11, November – 2021
Title:
35.EFFICACY OF NSAIDS IN POST-ERCP PANCREATITIS
Authors :
Dr. Ahmad Burhan, Dr. Noor Altaf, Dr. Syed Saad Ali Chishti
Abstract :
Objective: To determine efficacy of diclofenac suppository in reducing post-ERCP pancreatitis (PEP) and identify risk factors for PEP.
Methods: This is a placebo-based prospective study at Department of Medicine, DHQ Teaching Hospital, Sargodha performed from January 2018 to June 2019. Patients were randomized to receive diclofenac suppository or glycerine suppository before ERCP. Both groups were compared for PEP using chi square x2 test while risk factors for PEP were determined using binary logistic regression.
Results: Total of 165 patients with mean age 49.1(±15.2) and male to female ratio 1/1.6 (63/102) were included. Among 82 (49.7%) patients in diclofenac group, 8 (9.7%) developed pancreatitis while 19(22.9%) of 83(50.3%) in placebo group had PEP (p value 0.02). After multivariate analysis, age>45 years (p value 0.014, OR 3.2), Bilirubin >3 mg/dl (p value 0.004 OR 3.58), time to cannulation> 5 minutes (p value<0.000 OR 9.2), use of precut (p value< 0.000 OR 4.9), pancreatic duct cannulation (p value 0.000 OR 5.46) and total procedure time >30 minutes (p value 0.01 OR 3.92) were risk factors for PEP.
Conclusion: Pre-procedure Diclofenac suppository reduces post-ERCP pancreatitis. Age > 45 years, serum bilirubin > 3 mg/dl, cannulation time > 5 minutes, use of precut, pancreatic duct cannulation and procedure time > 30 minutes are risk factors for post-ERCP pancreatitis.
Cite This Article:
Please cite this article in press Ahmad Burhan et al, Efficacy Of Nsaids In Post-Ercp Pancreatitis ., Indo Am. J. P. Sci, 2021; 08(11).
Number of Downloads : 10
References:
1 McCune WS, Shorb PE, Moscovitz H. Endoscopic cannulation of the ampulla of vater: a preliminary report. Ann Surg. 1968;167(5):752-756. doi: 10.1097/00000658-196805000-00013
2 Matsushita M, Koyabu M, Nishio A, Seki T, Okazaki K. Techniques of ERCP with a conventional endoscope in pancreatoduodenectomy anatomy. Gastrointest Endosc. 2017;86:747-748. doi: 10.1016/j.gie.2017.05.007
3 Guda NM, Freeman ML. Overview of ERCP Complications: Prevention and Management. Lee LS, editor ERCP and EUS: A Case-Based Approach. New York: Springer. 2015;37-56. doi: 10.1007/978-1-4939-2320-5
4 Kahaleh M, Freeman M. Prevention and management of post-endoscopic retrograde cholangiopancreatography complications. Clin Endosc 2012;45:305-312. doi: 10.5946/ce.2012.45.3.305
5 Mine T, Morizane T, Kawaguchi Y, Akashi R, Hanada K, Ito T, et al. Clinical practice guideline for postERCP pancreatitis. J Gastroenterol. 2017;52:1013-1022. doi: 10.1007/s00535-017-1359-5
6 Zhou W, Li Y, Zhang Q, Li X, Meng W, Zhang L, et al. Risk factors for postendoscopic retrograde cholangiopancreatography pancreatitis: A retrospective analysis of 7,168 cases. Pancreatology. 2011;11(4):399-405. doi: 10.1016/S1424-3903(11)80094-3
7 Freeman ML, Guda NM. Prevention of post-ERCP pancreatitis: a comprehensive review. Gastrointest Endosc. 2004;59:845-864. doi: 10.1016/S0016-5107(04)00353-0
8 Zhang H, Cho J, Buxbaum J. Update on the Prevention of Post-ERCP Pancreatitis. Curr Treat Options Gastroenterol. 2018;16:428-440. doi: 10.1007/s11938-018-0194-y
9 Andrade-Davila VF, Chavez-Tostado M, Davalos-Cobián C, Garcia-Correa J, Montano-Loza A, Fuentes-Orozco C, et al. Rectal indomethacin versus placebo to reduce the incidence of pancreatitis after endoscopic retrograde cholangiopancreatography: results of a controlled clinical trial. BMC Gastroenterol. 2015;15:85. doi:10.1186/s12876-015-0314-2
10 Elmunzer BJ, Scheiman JM, Lehman GA, Chak A, Mosler P, Higgins PD, et al. U. S. Cooperative for Outcomes Research in Endoscopy (USCORE). A randomized trial of rectal indomethacin to prevent post-ERCP pancreatitis. N Engl J Med. 2012;366:1414-1422. doi:10.1056/NEJMoa1111103
11 Otsuka T, Kawazoe S, Nakashita S, Kamachi S, Oeda S, Sumida C, et al. Low-dose rectal diclofenac for prevention of post-endoscopic retrograde cholangiopancreatography pancreatitis: a randomized controlled trial. J Gastroenterol. 2012;47:912-917. doi: 10.1007/s00535-012-0554-7
12 Dobronte Z, Szepes Z, Izbeki F, Gervain J, Lakatos L, Pecsi G, et al. Is rectal indomethacin effective in preventing of post-endoscopic retrograde cholangiopancreatography pancreatitis? World J Gastroenterol. 2014;20:10151-10157. doi: 10.3748/wjg.v20.i29.10151
13 Dumonceau JM, Andriulli A, Elmunzer J, Mariani A, Meister T, Deviere J, et al. Prophylaxis for Post-ERCP pancreatitis: European Society of Gastrointestinal endoscopy (ESGE) Guidelines- Updated June 2014.
14 Endoscopy. 2014;46:799-815. doi: 10.1055/s-0034-1377875
15 Banks PA, Bollen TL, Dervenis C, Gooszen HG, Johnson CD, Sarr MG, et al. Acute Pancreatitis Classification Working Group. Classification of acute pancreatitis–2012: revision of the Atlanta classification and definitions by international consensus. Gut. 2013;62:102-111. doi: 10.1136/gutjnl-2012-302779
16 Syren E, Eriksson S, Enochsson L, Eklund A, Sandblom G. Risk factors for pancreatitis following endoscopic retrograde cholangiopancreatography. BJS Open. 2019;3(4):485-489. doi: 10.1002/bjs5.50162
17 Testoni PA, Mariani A, Giussani A, Vailati C, Masci E, Macarri G et al. Risk factors for post-ERCP pancreatitis in high and low volume centers and among expert and non expert operators: a prospective multicenter study. Am J Gastroenterol. 2010;105:1753-1761. doi: 10.1038/ajg.2010.136
18 Li GZ, Wand G, Fang J, Zha HL, Zhao Q. Risk factors for post-ERCP pancreatitis: Evidence from 1786 cases. Med Sci Monit. 2018;24:8544-8552. doi: 10.12659/MSM.913314
19 Kang X, Zheng L, Zeng W, Yang S, Sun H, Zhang R, et al. Risk factors for Post-ERCP pancreatitis in high risk patients receiving Post-procedure rectal indomethacin. J Gastrointest Surg. 2018;22(11):1903-1910. doi: 10.1007/ s11605-018-3864-0
20 Leghari A, Ghazanfar S, Qureshi S, Taj MA, Niaz SK, Quraishy S. Frequency and risk factors in the post-ERCP pancreatitis in a tertiary care centre. J Coll Physicians Surg Pak. 2013;23(9):620-624. doi: 09.2013/JCPSP.620624
21 Liu L, Li C, Huang Y, Jin H. Nonsteroidal anti-inflammatory drugs for endoscopic retrograde cholangiopancreatography postoperative pancreatitis prevention: a systematic review and meta-analysis. J Gastrointest Surg. 2019;23(10):1991-2001. doi: 10.1007/s11605-018-3967-7
22 Serrano JPR, de Moura DTH, Bernardo WM, Ribeiro IB, Franzini TP, de Moura ETH, et al. Nonsteroidal antiinflammatory drugs versus placebo for post-endoscopic retrograde cholaniopancreatograaphy pancreatitis: a systematic review and meta-analysis. Endosc Int Open. 2019;7(4): E477-E486. doi: 10.1055/a-0862-0215
23 Lopes L, Canena J. ERCP in Portugal: a wide survey on the prevention of Post-ERCP pancreatitis and papillary cannulation techniques. GE Port J Gastroenterol. 2018;26(1):14-23. doi: 10.1159/000487150
24 Hanna MS, Portal AJ, Dhanda AD, Przemioslo R. UK wide survey on the prevention of post-ERCP pancreatitis. Frontline Gastroenterol. 2014;5(2):103-110.